ALEC实时信号 | 通过Getagraph.com最大化利润

出售 137973 min ago

@ $6.07

发出时间: 14 Feb 2024 @ 04:46

回报率: -10.38%

上一信号: Feb 13 - 22:30

上一信号: 购买

回报率: -2.10 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Stats
今日成交量	529 526
平均成交量	600 068
市值	524.33M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $-0.500 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.91
ATR14	$0.00700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	500 000	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Buy	98 533	Common Stock
2024-04-30	Polaris Venture Management Co. Vi, L.l.c.	Sell	98 533	Common Stock
2024-03-19	Altmeyer Mark	Buy	41 250	Common Stock
2024-03-19	Altmeyer Mark	Buy	19 420	Stock Option (right to buy)

INSIDER POWER
-25.53
Last 100 transactions
Buy: 2 784 515 \| Sell: 4 159 752

音量相关性

長: 0.25 (neutral)

短: 0.71 (moderate)

Signal:(73.417) Neutral

Alector Inc 相关性

10 最正相关
AEHR	0.894
NEOG	0.893
VMAR	0.891
BROG	0.89
EHTH	0.889
LCID	0.885
EVOK	0.876
RVNC	0.876
NDRA	0.874
TXG	0.871

10 最负相关
BSCO	-0.847
ESTA	-0.83
NESR	-0.823
OXSQ	-0.82
PTMN	-0.817
LPCN	-0.811
SFBC	-0.81
KRUS	-0.808
IMPP	-0.805
AEAE	-0.802

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Alector Inc 相关性 - 货币/商品

0.23
( neutral )

0.11
( neutral )

0.00
( neutral )

-0.40
( neutral )

0.52
( weak )

Alector Inc 财务报表

Annual	2023
营收:	$97.06M
毛利润:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2023
营收:	$97.06M
毛利润:	$88.21M (90.88 %)
EPS:	$-1.560

FY	2022
营收:	$133.62M
毛利润:	$125.15M (93.66 %)
EPS:	$-1.620

FY	2021
营收:	$207.09M
毛利润:	$0.00 (0.00 %)
EPS:	$-0.467

Financial Reports:

No articles found.

Alector Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.